The Office of Technology Licensing was established in 1970 to transfer technologies developed at Stanford. Find out more about OTL's history, mission, staff, and statistics.

Login to TechFinder » 

p53-VP16 chimera knock-in mouse


Stanford Reference:

02-299


Abstract


Researchers in Dr. Laura Attardi’s lab have created a knock-in mouse strain which generates a form of p53 that is not subject to degradation by the proteasome. p53 is a tumor suppressor protein that senses and responds to cellular stress and is crucial for genomic stability and thus is involved in preventing cancer. In this mouse the wild-type p53 locus is replaced with a p53-VP16 fusion; such that the p53 transactivation domain is replaced with that of the VP16 transactivator protein. The p53-VP16 is silenced through an upstream floxed transcriptional stop element until Cre recombinase is expressed and the transcriptional stop element is excised. Furthermore, the Mdm-2 ubiquitin ligase binding domain has been removed thereby increasing the stability of p53. This mouse will serve as a useful model for investigating and developing p53-based cancer therapeutics.

Stage of Research
The inventors demonstrated, through analysis of mouse embryo fibroblasts derived from these mice, that upon activation of the p53-VP16 gene there is very potent growth suppression. In addition, they have shown that this fusion protein is like wild-type p53 in its ability to activate p53 target genes.


Applications


  • Basic and pre-clinical research tool for:
    • Development of cancer therapeutics.
      • Including potential for development of the fusion protein as a therapeutic for tumors lacking p53.
    • Study of p53 activities and function.

Advantages


  • Mice can show proof-of-principle efficacy in tumor suppression/regression in vivo.
  • The p53-VP16 fusion protein, as compared to wild-type p53,:
    • Has the same growth suppression and target gene activation activities.
    • Is more stable.
    • Is more potent.
    • Has the potential to be a more effective cancer therapeutic.

Publications



Related Web Links



Innovators & Portfolio



Date Released

 10/31/2012
 

Licensing Contact


Brenda Martino, Biological Materials Specialist
(650) 725-9119 (Direct)
Login to Request Information

[-] Map/Timeline

92-146 Achieving B-Cell Lymphoma Growth Modulation and Enhanced Tumor Resistance Using Idiotype/Cytokine Conjugates
97-168 Recombinase-Mediated Site Specific Integration ("Wildtype" recombinases)
97-236 Alpha 2a Adrenergic Receptor Gene Disruption Mouse (A2aARGDM)

more technologies

Related Keywords


p53   research: cancer   gene therapy   mouse model   mouse   therapeutic: gene therapy   therapeutic: anticancer   genomics: transgenic animals   animal model   Cancer Gene Therapy   research tool: mouse model   
 

   

  

Also of Interest...
92-146 Achieving B-Cell Lymphoma Growth Modulation and Enhanced Tumor Resistance Using Idiotype/Cytokine Conjugates
97-168 Recombinase-Mediated Site Specific Integration ("Wildtype" recombinases)
97-236 Alpha 2a Adrenergic Receptor Gene Disruption Mouse (A2aARGDM)

Recently Viewed...
S02-299 p53-VP16 chimera knock-in mouse